Genomma Lab achieves a 48.0% Top Line Growth and an EBITDA Growth of 50.6% during 3Q10

GENOMMA LAB INTERNACIONAL ANNOUNCES ITS THIRD QUARTER 2010 RESULTS

Mexico City, Mexico – October 28, 2010

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2010. All figures included herein were prepared in accordance with Mexican GAAP and are stated in nominal Mexican pesos.

3Q 2010 Highlights (vs. 3Q 2009)

- Net Sales for the quarter reached Ps. 1,663.5 million, increasing 48.0%.
- EBITDA[1] rose 50.6% to Ps. 430.5 million, representing a 25.9% margin during the period.
- Consolidated Net Income increased 57.1%, to Ps. 292.4 million. This represents a 17.6 % margin during the period.
- Earnings per Share[2] increased 71.8% to Ps. 0.94.
- International Net Sales rose 143.8% to Ps. 457.8 million.
- During the third quarter Genomma Lab successfully launched 55 products under 14 existing brands and 4 products under 3 New Brands[3].
- Also, during the third quarter of 2010 the Company completed 4 acquisitions and 1 licensing agreement. Additionally, in October Genomma Lab signed 5 more acquisitions, which are subject to regulatory approvals.

---

[1] EBITDA is calculated by adding depreciation and amortization to the Operating Income.
[2] Earnings Per Share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.
[3] As defined below.

Contact: Oscar Villalobos
Tel: +52 (55) 5081 0000 Ext. 4250
E-mail: inversion@genommalab.com

In New York: Grayling USA
Tel: +1 (646) 284-9400
E-mail: genommalab@grayling.com

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: "I am glad to announce that we continued to deliver solid growth and profitability during the third quarter of 2010. Despite not entering the price war in the retail market, our operations in Mexico along with our international operations drove the significant sales and profitability increases during this quarter. Our base brands' performance reflected a strong sell-in, as clients' inventory levels returned to normal levels, translating into significant growth for the Company during this third quarter. All of us at Genomma Lab are pleased to see that the results so far in 2010 are in line with the expectations set forth in our guidance.

As for our international operations, we continue to see outstanding results and significant growth in all markets especially in Brazil, Colombia, and Argentina. Our recent incursion into the United States continues to develop as expected, setting the footprint for 2011, as our process of cataloging continues with retailers such as Walgreens and Wal-Mart. These positive developments have offset the lower than expected sales performance of our *Primer Nivel por tu Salud* brand. Our international operations represent a significant part of our sales and are becoming more relevant.

Consolidated Results of Operations for the Third Quarter of 2010

The following table shows condensed and consolidated results of operations, in millions of pesos (except share and per-share data); the margin for each concept, as a percentage of Net Sales, as well as the variation in terms of percentage for the quarter ended September 30, 2010 and for the period beginning January to September 2010 are compared to the same periods of 2009:

For the quarter ended and accumulated to September 30, 2010 and 2009
(In millions of current Mexican Pesos)

	Third Quarter			January to September		
	2010	2009	%Var	2010	2009	%Var
Net Sales	1,663.5	1,123.7	48.0	4,120.3	2,758.3	49.4
Gross Profit	1,194.1	783.7	52.4	2,944.6	1,985.8	48.3
Gross Margin	71.8%	69.7%	2.0	71.5%	72.0%	(0.5)
EBITDA[1]	430.5	285.9	50.6	938.0	630.0	48.9
EBITDA Margin	25.9%	25.4%	0.4	22.8%	22.8%	(0.3)
Operating Income	413.5	273.8	51.0	884.9	602.8	46.8
Operating Income Margin	24.9%	24.4%	0.5	21.5%	21.9%	(0.4)
Net Income of Majority Shareholders	286.0	184.5	55.1	610.8	381.4	60.1
Net Income of Majority Shareholders Margin	17.2%	16.4%	0.8	14.8%	13.8%	1.0
Weighted average number of shares outstanding	1,052,589,426	1,053,461,078	(0.1)	1,052,686,276	1,055,122,201	(0.2)
EPS (12 months)[2]	0.94	0.55	71.8	0.94	0.55	72.1

[1] EBITDA is calculated by adding Depreciation and Amortization to the Operating Income.

[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of September 30, 2010 totaled 1,052,589,426.

Net Sales rose 48.0% to Ps. 1,663.5 million for the third quarter of 2010, from Ps. 1,123.7 million for the third quarter of 2009. This increase resulted from the combination of the following: i) a 55.4% increase (Ps. 281.6 million) from **Base Brands** in Mexico, amounting to Ps. 789.6 million, including line extensions on these brands; ii) a 72.5% increase (Ps. 120.0 million) due to the full year effect of **Prior Year Launches** in Mexico, including the recent line extensions on these brands launched during 2010 to reach Ps. 285.5 million; iii) a 67.2% decrease (Ps. 176.2 million) in sales of our **Primer Nivel por tu Salud** brand portfolio due mainly to the high comparative base in the third quarter of 2009 when the brand was launched and our customers' inventory buildups were reflected in our sales, to reach Ps. 86.1 million; iv) Ps. 44.4 million in the third quarter of 2010 from **New Brands** in Mexico related to the launch of 14 new products under 7 New Brands; and, iv) a 143.8% increase (Ps. 270.0 million) coming from **International** operations totaling Ps. 457.8 million.

During the third quarter, Genomma Lab successfully launched, as part of its line extension strategy, 55 products under 14 existing brands (Base Brands[4] and Prior Year Launches[5]), 30 of which were launched under the brands *Teatrical, Flor de Naranja Sanborns*, and *Jockey Club,* which were acquired last year. The Company also launched during the third quarter 4 products under 3 New Brands[6], as part of its new product launch plan.

Net Sales by brands are classified as follows:

1) **Base Brands** represent brands launched at least two years prior to the last fiscal year (2008, 2007, 2006, and earlier),
2) **Prior Year Launches** are brands launched during the prior fiscal year (2009),
3) **Primer Nivel por tu Salud** is our brand of generic products,
4) **New Brands** are brands launched during the current fiscal year (2010), and
5) **International** refers to Net Sales of brands from our international operations.

[4] As defined below.
[5] As defined below.
[6] As defined below.

The following table shows Net Sales year to date, as of September of 2010 and 2009 detailed by brand:

(In millions of current Mexican Pesos)

BRAND	NET SALES YTD 10	% OF TOTAL NET SALES	NET SALES YTD 09	VAR %
PRIMER NIVEL	308.1	*7.5%*	262.3	17.4%
ASEPXIA	266.9	*6.5%*	234.3	13.9%
UNESIA	197.7	*4.8%*	28.5	594.0%
NIKZON	172.0	*4.2%*	119.6	43.8%
NEXT	159.5	*3.9%*	46.8	240.5%
GOICOECHEA	140.3	*3.4%*	119.9	17.0%
SHOT B	132.6	*3.2%*	60.2	120.2%
METABOL TONICS	119.7	*2.9%*	118.3	1.2%
LINEA M	112.0	*2.7%*	143.8	-22.1%
SILKA MEDIC	111.5	*2.7%*	82.7	34.9%
QG5	101.3	*2.5%*	75.4	34.3%
GENOPRAZOL	100.8	*2.4%*	69.5	44.9%
TIO NACHO	99.1	*2.4%*	35.4	179.9%
DALAY	95.6	*2.3%*	73.2	30.7%
X RAY	95.3	*2.3%*	62.4	52.7%
SUBTOTAL	2,212.5	*53.7%*	1,532.4	44.4%
OTHER BRANDS	852.7	*20.7%*	798.3	6.8%
TOTAL MEXICO	3,065.2	*74.4%*	2,330.7	31.5%
INTERNATIONAL	1,055.0	25.6%	427.6	146.7%
TOTAL	**4,120.3**	**100.0%**	**2,758.3**	**49.4%**

Gross Profit increased 52.4% to Ps. 1,194.1 million for the third quarter 2010, compared to Ps. 783.7 million during the third quarter of 2009. Gross Margin increased 2.1 percentage points, as a percentage of Net Sales, to 71.8% in the third quarter of 2010, compared to 69.7% in the same period of 2009. This increase was primarily due to a lower weight in overall sales from our *Primer Nivel por tu Salud* brand, which has a higher cost of goods sold as a percentage of Net Sales, compared to last year's third quarter.

Selling, General and Administrative Expenses, as a percentage of Net Sales, increased 1.5 percentage points to 46.9% for the third quarter of 2010 from 45.4% for the third quarter of 2009. This increase was mainly associated with higher advertising expenses derived from the launch of new products, which include several products from last year's acquisitions, and was partially offset by corporate leverage in other SG&A expenses achieved by the increase in Net Sales during the third quarter of 2010 compared to the same period of 2009.

EBITDA increased 50.6% to Ps. 430.5 million in the third quarter of 2010, compared to Ps. 285.9 million in the third quarter of 2009. The EBITDA margin increased 0.5 percentage points as a percentage of Net Sales to 25.9% for the third quarter of 2010 from 25.4% for the third quarter of 2009. The EBITDA margin increase was primarily due to a 2.1 percentage points decline in the cost of goods sold as a percentage of Net Sales and was partially offset by a 1.5 percentage points increase in the Selling, General and Administrative Expenses (excluding Depreciation and Amortization) as a percentage of Net Sales.

EBITDA Reconciliation

For the quarters ended September 30, 2010 and 2009
(In thousands of current Mexican pesos)

	Third Quarter	
	2010	2009
Consolidated net income (loss)	292.4	186.1
Discontinued operations	-	(1.8)
Income tax expense (benefit)	120.7	108.0
Not consolidated subsidiaries (income)	3.8	-
Comprehensive financing (income) cost	(5.2)	(19.8)
Other expense (income), net	1.9	1.3
Operation income	**413.5**	**273.8**
Depreciation and amortization	17.0	12.1
EBITDA	**430.5**	**285.9**
EBITDA margin	*25.9%*	*25.4%*

Operating Income increased 51.0% to Ps. 413.5 million for the third quarter of 2010 compared to Ps. 273.8 million for the third quarter of 2009. Operating Margin increased 0.5 percentage points, as a percentage of Net Sales, to 24.9%, compared to 24.4% for the same period in 2009. This increase is a result of the aforementioned reasons.

Comprehensive Financing Income resulted in a Ps. 5.2 million gain for the third quarter of 2010, which represented a decrease of Ps. 14.6 million compared to the Ps. 19.8 million in the third quarter of 2009. This decrease was primarily a result of: i) lower Foreign Exchange Income that reached Ps. 3.1 million during the third quarter of 2010 from Ps. 15.5 million during the same period of 2009; ii) an increase in Financial Expenses of Ps. 3.4 million to Ps. 5.4 million during the third quarter of 2010 compared to Ps. 2.0 million during the same period of 2009; iii) a lower Interest Income of Ps. 5.8 million during the third quarter of 2010 from Ps. 6.3 million in the same period of 2009; iv) an increase in the Monetary Position Loss to Ps. 2.4 million in the third quarter of 2010 from Ps. 1.4 million in the same period of 2009; and v) an increase of Ps. 2.8 million in the effects of the Exchange Rate from Foreign Operations to 4.1 million in the third quarter of 2010 from Ps. 1.3 million during the same period of 2009. As of September 30, 2010, the Company maintained a U.S. dollar treasury position of US$ 14.5 million and a total cash position of Ps.786.3 million.

Consolidated Net Income increased 57.1% to Ps. 292.4 million for the third quarter of 2010 compared to Ps. 186.1 million for the third quarter of 2009. This is a result of all of the above mentioned reasons.

Balance Sheet

As of September 30, 2010, December 31, 2009 and September 30, 2009

(In millions of current Mexican pesos for the amounts of September 2010, December 2009 and September 2009)

	September 30, 2010	September 30, 2009	Var Sept '10 vs Sept '09	% Var Sept '10 vs Sept'09	December 31, 2009	Var Sept '10 vs Dec '09	% Var Sept '10 vs Dec '09
Balance Sheet Information:							
Cash and equivalents	**786.3**	1,019.2	(232.9)	-22.8%	1,059.4	(273.1)	-25.8%
Trade receivables	**2,112.3**	1,080.7	1,031.6	95.5%	1,336.9	775.4	58.0%
Inventories	**805.5**	647.0	158.6	24.5%	630.1	175.4	27.8%
Other current assets	**314.1**	298.7	15.4	5.2%	340.6	(26.5)	-7.8%
Total Assets	**5,150.4**	3,755.9	1,394.4	37.1%	4,241.7	908.7	21.4%
Suppliers	**723.3**	564.6	158.7	28.1%	594.3	129.0	21.7%
Other current liabilities	**668.0**	341.2	326.8	95.8%	427.0	241.0	56.4%
Loans with financial institutions	**-**	-	-		-	-	
Total Liabilities	**1,504.4**	1,080.9	423.5	39.2%	1,190.9	313.5	26.3%
Stockholders Equity	**3,645.9**	2,675.0	970.9	36.3%	3,050.7	595.2	19.5%
Working Capital (1)	**2,626.9**	2,139.7	487.2	22.8%	2,345.7	281.2	12.0%
Working Capital less cash	**1,840.6**	1,120.5	720.1	64.3%	1,286.3	554.3	43.1%
Trade Recevables days	**131**	111	20	18.5%	109	22	20.8%
Inventories days	**177**	239	(62)	-25.9%	183	(6)	-3.6%
Suppliers days	**159**	208	(49)	-23.8%	173	(14)	-8.2%
Cash Conversion Cycle	**149**	141	8	5.8%	119	30	25.4%

(1) Working capital consists of current assets minus current liabilities.

Cash and Equivalents decreased 22.8% (Ps. 232.9 million) to Ps. 786.3 million as of September 30, 2010, compared to Ps. 1,019.2 million as of September 30, 2009. This decrease was mainly due to cash consumption related to the acquisition of our corporate headquarters in the amount of Ps. 143.7 million, and brand acquisitions paid during the last twelve months totaling Ps. 175.3 million. In addition, there were important outflows related to the funding of the Brazilian and US operations, as well as working capital requirements in order to fund the achieved business growth. This decrease was partially offset by the Company's cash generation during the last twelve months.

Trade Receivables increased 95.5% (Ps. 1,031.6 million) to Ps. 2,112.3 million as of September 30, 2010, from Ps. 1,080.7 million as of September 30, 2009. Days of Trade Receivables increased 20 days, to 131 as of September 30, 2010, from 111 as of September 30, 2009. This increase was mainly due to a year-end commercial strategy in which payment terms were extended. Additionally, our recent launches during the quarter have contributed to the extension of payment terms.

Inventories increased 24.5% (Ps. 158.6 million) to Ps. 805.5 million as of September 30, 2010, from Ps. 647.0 million as of September 30, 2009. Days of Inventories decreased 62 days, to 177 as of September 30, 2010, from 239 as of September 30, 2009. This decrease is due primarily to a more efficient inventory management in our distribution center.

Suppliers increased 28.1% (Ps. 158.7 million) to Ps. 723.3 million as of September 30, 2010, from Ps. 564.6 million as of September 30, 2009. Days of Suppliers decreased 49 days, to 159 as of September 30, 2010, from 208 as of September 30, 2009. This decrease was primarily a result of the full year effect of our *Primer Nivel por tu Salud* initiative, which had special credit terms negotiated for the launch.

Other Current Assets increased 5.2% (Ps. 15.4 million) to Ps. 314.1 million as of September 30, 2010, from Ps. 298.7 million as of September 30, 2009.

Other Current Liabilities increased 95.8% (Ps. 326.8 million) to Ps. 668.0 million as of September 30, 2010, from Ps. 341.2 million as of September 30, 2009. This change was mainly attributable to an increase in payable advertising as part of the normal payment terms agreed with TV stations, combined with an increase in income taxes payable.

During the third quarter of 2010 the Company's liquidity requirements were funded by cash flow from our operations and cash on hand.

Operations Summary

Net Sales for the Third Quarter

For the third quarter of 2010, Net Sales of our OTC pharmaceutical products in Mexico increased 97.2%[7], compared to the third quarter of 2009. During the third quarter of 2010, the Company launched 7 new OTC products.

Net sales of our personal care products in Mexico increased 28.1%[8] for the third quarter of 2010, compared to the third quarter of 2009. During the third quarter of 2010 the Company launched 52 new personal care products.

[7] Includes only OTC pharmaceutical products in Mexico.
[8] Includes only personal care products in Mexico.

Net sales from our international operations increased 143.8% to Ps. 457.8 million for the third quarter of 2010, compared to Ps. 187.8 million for the same period in 2009. This increase was mainly driven by sales from our new operations in the Brazilian and US markets, as well as a significant growth rate registered in the rest of our Latin American operations, lead by Argentina and Colombia.

New Products Launches and Line Extensions

During the third quarter of 2010, we have launched 55 line extensions of our **Base Brands** and **Prior Year Launches;** and 4 new products under 3 **New Brands**; among which are:

Teatrical Alisante Lipodrenante, Teatrical Humectante Blanqueadora +UV and Teatrical Clásica con Lanolina are line extensions of our *Teatrical* brand, which was purchased in June 2009 due to its great strength and tradition in Mexico. *Teatrical Alisante Lipodrenante* is a firming body lotion, anti-orange skin with silk and oatmeal. *Teatrical Humectante Blanqueadora +UV* is a lightening body lotion with silk and pearl shell. *Teatrical Clásica con Lanolina* is a moisturizing face and body lotion with lanolin.

Tío Nacho Soap and Tío Nacho Conditioner are line extensions of our *Tío Nacho* brand, which was purchased in 2008 for its top of mind recognition in the shampoo category. *Tío Nacho Soap* is a body gel that nourishes, hydrates, and helps reduce signs of skin aging. *Tío Nacho Conditioner*, with its chamomile formula, restores and lightens hair.

Alliviax is a new brand that consists of an anti-inflammatory treatment that helps relieve muscular pains, sore throat, and colic.

Other Corporate Events

- On September 1st, 2010 Genomma Lab was included as part of the Mexican Stock Exchange Index (IPC). Entering this index has increased the Company's liquidity. As of September 30th Genomma Lab was positioned as the 15th most liquid company in the Mexican Stock Exchange.
- In the third quarter and during the subsequent month Genomma Lab acquired 9 well-positioned brands and 1 licensing agreement to strengthen its presence in the following markets:

- Shampoo and conditioner categories, with brands such as ***Vanart, Galaflex, and Santé***. This last brand also opens the door in the naturist market.
- Anti-micotic lotion and powder segments, with ***Micotex***.
- Nasal hydration category, in which we will participate with ***Nasalub.***
- Ophthalmological care category, in which we will participate with the licensing agreement to use ***Devlyn,*** a brand with a solid growth and positioning in the Mexican market.
- Hair coloring market, with ***Affair,*** a brand that offers products for women.
- Ointment market, with ***Pomada de la Campana***, a popular traditional brand in Mexico with a relevant positioning among the segment, and that has remained in the consumer's mind for many generations over the past 100 years.
- Powder, lotion, and deodorant categories, with ***Ossart,*** a well-known and traditional brand in Mexico.
- Men's personal care market, with ***English Leather***, a brand with a long standing level of recognition among the fragrance, lotion, and deodorant categories.

➢ The Trust 414, the largest shareholder of the Company, transferred today to one of its trustees, a number of the Company's shares that represents more than 5% of the total equity. As a result, the number of shares outstanding held by public investors increased approximately to 55% of the total outstanding stock. It is worth highlighting that the main shareholder of the Company maintains the same holdings of the Company's stock announced during the Initial Public Offering on June 2008 and has not sold any shares.

Additionally, and effective as of today, October 28th 2010, Mr. Arturo Iván Gamboa Rullán submitted his resignation to the Board of Directors as Proprietary Member of the Board, Member of the Executive Committee, and Executive Vice-president of the Company, as he is moving his permanent residence to another country. Mr. Gamboa has not been involved in the Company's day-to-day operations since the Initial Public Offering on the Mexican Stock Exchange on June 2008; therefore, the resignation will have no effects on the Company's operation. Also, his alternate in the Board of Directors of the Company submitted his resignation to such position.

In today’s session the Board of Directors decided to schedule a Shareholders Meeting to consider the resignation and new Board Member designation, among other topics.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker symbol “LAB.B” (Bloomberg: labb.mx).

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three month and nine month periods ended September 30, 2010 and 2009
(In thousands of current Mexican pesos)

	Third Quarter			Acumulated		
	2010	2009	% Var	2010	2009	% Var
Net sales	1,663,462	1,123,719	48%	4,120,284	2,758,296	49%
Costs and expenses:						
Cost of sales	469,342	340,050	38%	1,175,708	772,546	52%
Selling, general and administrative expenses	780,616	509,910	53%	2,059,711	1,382,952	49%
Total costs and expenses	1,249,958	849,960	47%	3,235,419	2,155,497	50%
Income from operations	413,505	273,758	51%	884,865	602,798	47%
Other (expense)- Net	(1,923)	(1,278)	50%	12,021	(1,341)	-996%
Comprehensive financing income (cost)						
Interest (expense)	(5,367)	(1,963)	173%	(11,073)	(7,046)	57%
Interest income	5,790	6,349	-9%	22,302	33,728	-34%
Exchange gain (loss)	3,147	15,535	-80%	(10,029)	(23,070)	-57%
Monetary position (loss)	(2,440)	(1,423)	0%	(8,126)	(4,063)	0%
Effects of exchange rate changes on foreign operations	4,090	1,298	0%	11,403	1,365	0%
	5,220	19,795	-74%	4,478	914	390%
Income of not consolidated subsidiaries	(3,759)	-	0%	(14,221)	-	0%
Income before income taxes	413,042	292,275	41%	887,143	602,371	47%
Income tax expense (benefit)	120,691	107,969	12%	265,320	219,163	21%
Discontinued operations (loss)	-	1,799	-100%	-	738	-100%
Consolidated net income (loss)	292,350	186,105	57%	621,823	383,946	62%
Consolidated net income (loss)	292,350	186,105	57%	621,823	383,946	62%
Net loss (income) of minority stockholders	(6,301)	(1,626)	0%	(10,989)	(2,518)	0%
Net income of majority stockholders	286,049	184,479	55%	610,834	381,428	60%

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of September 30, 2010; September 30, 2009; and December 31, 2009.
(In thousands of current Mexican Pesos)

	Sept - '10	Sept - '09	V Sept - '09 $	V Sept - '09 %	Dec - '09	V Dec - '09 $	V Dec - '09 %
Assets							
Current assets:							
Cash and equivalents	786,312	1,019,198	(232,886)	-22.8%	1,059,380	(273,068)	-25.8%
Share buy back fund	5,153	16,131	(10,978)	-68.1%	8,142	(2,989)	-36.7%
Employee Share buy back fund	1	15,499	(15,498)	-100.0%	10,894	(10,893)	-100.0%
Accounts receivable-Net	2,340,912	1,283,081	1,057,830	82.4%	1,545,647	795,264	51.5%
Inventory - Net	805,524	646,960	158,563	24.5%	630,121	175,403	27.8%
Prepaid expenses and other current assets	23,389	49,335	(25,946)	-52.6%	81,996	(58,607)	-71.5%
Due from related parties	56,921	15,371	41,550	270.3%	30,795	26,126	84.8%
Discontinued operations	3,130	23,191	(20,061)	-86.5%	3,407	(277)	-8.1%
Total current assets	**4,021,342**	**3,068,766**	**952,576**	**31.0%**	**3,370,383**	**650,959**	**19.3%**
Equipment- net	**407,073**	**163,245**	**243,827**	**149.4%**	**260,698**	**146,375**	**56.1%**
Trademarks	523,467	435,879	87,588	20.1%	446,653	76,814	17.2%
Investments in subsidiaries	10,147	-	10,147	0.0%	25,166	(15,020)	-59.7%
Deferred income tax	45,829	29,486	16,343	55.4%	2,869	42,960	1497.4%
Other assets- Net	142,506	58,138	84,367	145.1%	135,844	6,662	4.9%
	721,949	**523,935**	**198,013**	**37.8%**	**610,570**	**111,378**	**18.2%**
Total Assets	**5,150,363**	**3,755,947**	**1,394,416**	**37.1%**	**4,241,651**	**908,712**	**21.4%**
Current Liabilities:							
Trade accounts payable	723,311	564,616	158,695	28.1%	594,279	129,032	21.7%
Due to related parties	-	35	(35)	-100.0%	81	(81)	-100.0%
Accrued expenses and taxes other than income taxes	461,848	205,362	256,486	124.9%	389,295	72,553	18.6%
Payable tax (2)	206,164	135,844	70,320	51.8%	37,640	168,524	447.7%
Statutory employee profit sharing	4,139	5,164	(1,025)	-19.9%	3,382	756	22.4%
Discontinued operations	4,231	4,335	(104)	-2.4%	4,656	(425)	-9.1%
Deferred income tax	-	-	-		46,006	(46,006)	-100.0%
Employee retirement obligations	10,449	7,401	3,048	41.2%	7,491	2,958	39.5%
			-				
Trade accounts payable LP	94,295	158,156	(63,861)	-40.4%	108,090	(13,795)	-12.8%
			-				
Total Liabilities	**1,504,436**	**1,080,912**	**423,524**	**39.2%**	**1,190,920**	**313,516**	**26.3%**
Capital stock	1,931,222	274,924	1,656,299	602.5%	274,924	1,656,299	602.5%
Additional paid in capital	-	1,553,938	(1,553,938)	-100.0%	1,553,938	(1,553,938)	-100.0%
Retained earnings	1,141,685	519,636	622,049	119.7%	1,278,375	(136,690)	-10.7%
Net income	610,835	381,428	229,407	60.1%	-	610,835	#¡DIV/0!
Cumulative translation effects of foreign subsidiaries	(5,771)	2,065	(7,836)	-379.5%	1,228	(6,998)	-570.0%
Share buyback fund (1)	(52,555)	(64,816)	12,261	-18.9%	(69,415)	16,860	-24.3%
Net premium placement of repurchased shares	6,450	(221)	6,671	-	6,450	-	-
Superavit with related parties	(3,721)	-	(3,721)	-	(3,721)	-	-
Minority Interest	17,781	8,081	9,700	120.0%	8,953	8,828	98.6%
Total stockholders equity	**3,645,927**	**2,675,035**	**970,892**	**36.3%**	**3,050,731**	**595,196**	**19.5%**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the full year and third quarter of 2010
(In thousands of current Mexican pesos)

Operating activities:	Accumulated 2010	3Q 2010
Consolidated income for continued operations	621,823	292,351
Items related to investing activities:		
Depreciation and amortization	53,130	16,971
Unearned foreign exchange fluctuations	114	220
Income tax	265,320	120,691
Equity in loss of associated companies	14,221	3,759
Loss (gain) on sale of fixed assets	(557)	(557)
Other financing activites	-	-
Cash flow from operations	**954,051**	**433,435**
(Increase) Decrease in accounts receivable	(920,648)	(408,512)
(Increase) Decrease in inventories	(175,859)	(62,503)
Increase (Decrease) in accounts payable	282,102	247,891
Increase (Decrease) in payable income tax	(109,470)	(67,170)
Other, Net	36,583	(14,604)
Stock-based compensations cost	23,571	4,487
Discontinued operations	(109)	123
Changes in Working Capital	**(863,830)**	**(300,288)**
Net cash generated (used) in operating activities	**90,221**	**133,147**
Investing activities:		
Divestments (investments) in fixed assets	(189,004)	(33,381)
Asset sales (other capital expenditures)	(139,344)	(14,517)
Loss from discontinued operations	-	(38)
Net cash generated (used) in investing activities	**(328,348)**	**(47,936)**
Excess cash for (cash obtained from) financing activities	**(238,127)**	**85,211**
Financing activities:		
Repurchase of stocks	(41,040)	(29,938)
Payable interest from prior periods	-	-
Minority interest	(2,159)	(85)
Net cash used in financing activities	**(43,199)**	**(30,023)**
Net decrease in cash and cash equivalents before foreign exchange adjustments coming from International operations and inflationary effects.	**(281,326)**	**55,188**
Foreign exchange and inflationary effects from International operations	**(5,624)**	**(8,392)**
Net increase (decrease) in cash	**(286,950)**	**46,796**
Cash and cash equivalents beginning of period	**1,078,416**	**744,670**
Cash and cash equivalents end period balance	**791,466**	**791,466**
less- Employees' shares fund	1	1
less- shares buyback fund	5,153	5,153
Cash and cash equivalents at end period balance for operation	**786,312**	**786,312**